Journals / Türk Oftalmoloji Dergisi / 2017 / Cilt: 47 - Sayı: 6

The Knowledge of Eye Physicians on Local Anesthetic Toxicity and Intravenous Lipid Treatment: Questionnaire Study

Göz Hekimlerinin Lokal Anestezik Toksisitesi ve İntravenöz Lipit Tedavisi Hakkındaki Bilgileri: Anket Çalışması

Pages
320–325
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The importance of using 20% lipid emulsion in LATS treatment and having it available where LA is administered must be emphasized, and there should be compulsory training programs for ophthalmologists on this subject.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the knowledge of ophthalmologists regarding local anesthesia toxicity syndrome (LATS) and intravenous lipid emulsion used in treatment, and to raise awareness of this issue.
📊
Key Findings & Data:Materials and Methods: A questionnaire comprising 14 questions about demographics, local anesthesia (LA) use, toxicity, and treatment methods was administered to ophthalmologists at different hospitals.
💡
Conclusion & Impact:Conclusion: The importance of using 20% lipid emulsion in LATS treatment and having it available where LA is administered must be emphasized, and there should be compulsory training programs for ophthalmologists on this subject.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the knowledge of ophthalmologists regarding local anesthesia toxicity syndrome (LATS) and intravenous lipid emulsion used in treatment, and to raise awareness of this issue. Materials and Methods: A questionnaire comprising 14 questions about demographics, local anesthesia (LA) use, toxicity, and treatment methods was administered to ophthalmologists at different hospitals. Results: The study included 104 ophthalmologists (25% residents, 67.3% specialists, 7.7% faculty members) with a mean age of 35.71±6.53 years. The highest number of participants was from state hospitals (65.4%), and 34.6% of the physicians had been working in ophthalmology for more than 10 years. Seventy-six percent of the participants reported using LA every day or more than twice a week, but 56.7% had received no specific training on this subject. No statistically significant difference was observed between different education levels and the rates of training (p=0.419). Bupivacaine was the most preferred LA and the majority of respondents (97.1%) did not use a test dose. Allergy (76%) and hypotension (68.3%) were the most common responses for early findings of LATS, while cardiac arrest (57.4%) and hepatotoxicity (56.4%) were given for late findings. The most common responses concerning the prevention of LATS included monitorization (72.4%) and use of appropriate doses (58.2%). Symptomatic treatment was selected by 72.4% of respondents and cardiopulmonary resuscitation and antihistamine treatment by 58.8%. Of the ophthalmologists in the study, 62.5% had never encountered LATS. The use of 20% intravenous lipid emulsion therapy for toxicity was known by 65% of the physicians, but only 1 participant stated having used it previously. Conclusion: The importance of using 20% lipid emulsion in LATS treatment and having it available where LA is administered must be emphasized, and there should be compulsory training programs for ophthalmologists on this subject.

Özet

Amaç: Göz hekimlerinin lokal anestezi toksisitesi sendromu (LATS) ve tedavisinde kullanılan intravenöz lipit solüsyonu hakkındakibilgilerini gözden geçirerek, farkındalığı arttırması amaçlanmıştır.Gereç ve Yöntem: Değişik hastane ve görevlerdeki göz hekimlerinden, demografik bilgileri, lokal anestezik (LA) kullanımları,toksisite ve tedavi yöntemlerini sorgulayan toplam 14 soruluk anketi cevaplamaları istendi.Bulgular: Toplam 104 göz hekiminin (%25’i asistan, %67,3’ü uzman hekim ve %7,7’si öğretim üyesinin) katıldığı çalışmada, yaşortalaması 35,71±6,53 yıl idi. En yüksek katılım devlet hastanelerinden olup (%65,4), hekimlerin çoğunluğu (%34,6) bu branşta10 yıldan fazladır görev yapmaktaydı. Katılımcıların %76’sının LA’ları her gün ve haftada 2> kullandıkları, ancak çoğunluğunun(%56,7) bu konuda eğitim almadıkları görüldü. Tüm periyotlardaki çalışma süreleri ile eğitim alma oranları arasında istatistikselbir fark gözlenmedi (p=0,419). Bupivakain en çok tercih edilen LA iken, katılımcıların çoğu (%97,1) uygulama öncesi test dozukullanmamaktaydı. Toksisitenin erken dönem bulgularından allerji (%76) ve hipotansiyon (%68,3), geç dönem bulgularından kardiyakarrest (%57,4) ve hepatotoksisite (%56,4) yüksek oranlarda tercih edilirken, LATS’nin önlenmesinde %72,4 oranında monitorizasyonve %58,2 oranında uygun dozlarda kullanma cevapları verildi. Tedavide en çok semptomatik tedavi (%72,4) ve benzer oranlardakardiyopulmoner resusitasyon ve antihistaminik (%58,8) cevapları seçilirken, hekimlerin %62,5’inin LATS ile hiç karşılaşmadıklarıgörüldü. Hekimlerin %65’i toksisitede %20 lipit tedavisini daha önce duymadıklarını belirtirken, yalnızca 1 katılımcının bu solüsyonudaha önceden kullanmış olduğu belirlendi.Sonuç: Göz hekimlerinin LATS tedavisinde %20 lipit kullanımını ve lokal anestezi uyguladıkları yerlerde bu solüsyonu bulundurmalarıönemle vurgulanmalı ve bu konuda gerekli eğitim programı yapılmalıdır.

🔖

Cite This Article

ÖKSÜZ, G., URFALIOĞLU, A., URFALIOĞLU, S. (2022). The Knowledge of Eye Physicians on Local Anesthetic Toxicity and Intravenous Lipid Treatment: Questionnaire Study. Türk Oftalmoloji Dergisi, Cilt: 47 - Sayı: 6, 320–325. https://ajindex.com/articles/637875

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Jensen-Gadegaard P, Skjønnemand M, Damgaard-Jensen J, Gottschau B. Limited knowledge of lipid rescue therapy in local anaesthetic systemic toxicity. Dan Med Bul. 2011;58:4226. Dettoraki M, Dimitropoulou C, Nomikarios N, Moschos MM, Brouzas D. Generalized seizures and transient contralateral hemiparesis following retrobulbar anesthesia: a case report. BMC Anesthesiol. 2015;15:108. Carneiro HM, Oliviera B, Avila MP, Alves Neto O. Brainstem anesthesia after extraconal retrobulbar block. Can it be avoided? Case Report. Rev Bras Anestesiol. 2007;57:391-400.
  2. Quantock CL, Goswami T. Death potentially secondary to sub-Tenon’s block. Anaesthesia. 2007;62:175-177.
  3. Bensghir M, Badou N, Houba A, Balkhi H, Haimeur C, Azendour H. Convulsions during cataract surgery under peribulbar anesthesia: a case report. J Med Case Rep. 2014;8:218. Nicoll JM, Acharya PA, Ahlen K, Baguneid S, Edge KR. Central nervous system complications after 6000 retrobulbar blocks. Anesth Analg. 1987;66:1298-1302.
  4. Karasu D, Yılmaz C, Özgünay ŞE, Dayıoğlu M, Baytar Ç, Korfalı G. Knowledge of the research assistants regarding local anaesthetics and toxicity. Turk J Anaesthesiol Reanim. 2016;44:201-205.
  5. Başaranoğlu G, Teker MG, Saidoğlu L, Muhammedoğlu N, Özdemir H. Lokal anestezik kullanan hekimlerin toksisite ve intralipid tedavisi hakkında bilgileri. J Turk Anaest Int Care. 2010;38:262-267.
  6. Yaşar T, Çağlar Ç. Local injection anesthesias in ophthalmic surgery - Review. Turk J Ophthalmol. 2009;39:496-505.
  7. Süzer MA, Özhan MÖ, Eşkin MB, Atik B, Çaparlar C. Lipid infüzyonu kullanılarak başarıyla tedavi edilen bir lokal anestezik toksisitesi. J Turk Anaest Int Care. 2011;39:159-163.
  8. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006;105:217-218.
  9. Fettiplace MR, Weinberg G. Past, Present, and Future of Lipid Resuscitation Therapy. JPEN J Parenter Enteral Nutr. 2015;39(1 Suppl):72-83.
  10. Ciechanowicz SJ, Patil VK; Association of Anaesthetists of Great Britain and Ireland. Intravenous lipid emulsion-rescued at LAST. Br Dent J. 2012;212:237-241.
  11. Gosselin S, Morris M, Miller-Nesbitt A, Hoffman RS, Hayes BD, Turgeon AF, Gilfix BM, Grunbaum AM, Bania TC, Thomas SH, Morais JA, Graudins A, Bailey B, Megarbane B, Calello DP, Levine M, Stellpflug SJ, Hoegberg LC, Chuang R, Stork C, Bhalla A, Rollins CJ, Lavergne V; AACT Lipid Emulsion Therapy workgroup. Methodology for